Freenome Is A Biotechnology Company Based In South San Francisco, California, Founded In 2014. The Company Specializes In Developing Non-invasive Blood Tests For Early Cancer Detection, Utilizing Machine Learning, Genomics, And Multiomics Technologies. Freenome's Mission Is To Enhance The Accuracy And Accessibility Of Cancer Screening, Empowering Individuals To Prevent, Diagnose, And Treat Diseases. The Companys Core Technology Is Its Multiomics Platform, Which Integrates Various Biological Data Types To Analyze Cancer Signals In The Bloodstream. This Platform Supports The Detection Of Early-stage Cancer Through Liquid Biopsies, Which Are Blood Tests That Identify Genetic Material And Immune Responses Related To Cancer. Freenome Also Conducts Clinical Research To Validate Its Tests And Collaborates With Healthcare Providers, Pharmaceutical Companies, And Academic Institutions To Advance Precision Oncology. With A Team Of Approximately 625 Employees And Over $1.3 Billion In Funding, Freenome Is Committed To Transforming Cancer Diagnostics And Improving Patient Outcomes Through Innovative Blood-based Diagnostics.